02823nas a2200313   4500008004100000020001400041024001700055245014500072210006900217260028100286300001400567490000700581520163000588100001402218700002002232700001302252700001702265700001502282700001802297700002002315700002002335700001302355700001902368700001802387700002102405700001702426700001702443856004902460       2015                        eng d  a1537-2995  awdn, 041736000aFebrile reaction associated with the infusion of haploidentical peripheral blood stem cells: incidence, clinical features, and risk factors.0 aFebrile reaction associated with the infusion of haploidentical   aUnited StatesbChen,Yao. Peking University People's Hospital, Peking University Institute of Hematology, Beijing, People's Republic of China.Huang,Xiao-Jun. Peking University People's Hospital, Peking University Institute of Hematology, Beijing, People's Republic of Chic2015  a2023 - 310 v553 aBACKGROUND: We reported febrile reaction after the infusion of haploidentical peripheral blood stem cells (PBSCs). The aim of this study was to better characterize this new clinical entity named by infusion-related febrile reaction (IRFR)., STUDY DESIGN AND METHODS: A retrospective analysis of 490 patients received allogeneic stem cell transplantation (SCT) between October 2009 and December 2011 at our institution., RESULTS: The distribution of transplant type was 173 patients in HLA-identical siblings, 30 in unrelated, and 287 in haploidentical. IRFR was defined as unexplained fever of more than 38degreeC within 24 hours after the infusion of allogeneic PBSCs. We did not observe any IRFRs in patients undergoing HLA-identical sibling and unrelated transfusions. After excluding patients with a known source of infection, we classified haploidentical patients into IRFR and non-IRFR groups. Eighty-eight patients (30.7%) of 287 cases after the infusion of haploidentical PBSCs were diagnosed as IRFRs, chills in 3.5% (10/88), diarrhea in 21.6% (19/88), an erythematous skin rash in 0.3% (1/88), hypoxemia in 1.0% (3/88), and no other accompanying symptoms in 62.5% (55/88). Significantly higher elevation of C-reactive protein and complement C3 was seen in the IRFR group compared with the non-IRFR group. Multivariate analysis showed higher CD34+ dose was a significant predictor for IRFR (p = 0.023; hazard ratio=1.848; 95% confidence interval, 1.087-3.142)., CONCLUSION: As a clinical feature belonging to haploidentical SCT, IRFR was associated with the higher numbers of CD34+ from PBSCs.Copyright © 2015 AABB.1 aChen, Yao1 aHuang, Xiao-Jun1 aWang, Yu1 aLiu, Kai-Yan1 aChen, Huan1 aChen, Yu-Hong1 aZhang, Xiao-Hui1 aWang, Feng-Rong1 aHan, Wei1 aWang, Jing-Zhi1 aYan, Chen-Hua1 aZhang, Yuan-Yuan1 aSun, Yu-Qian1 aXu, Lan-Ping  uhttps://www.notifylibrary.org/reference/4409